Because most cancer chemopreventive agents have also anti-angiogenic properties in vitro and in vivo, further investigations [75] showed that XN repressed both the NF-κB and Akt pathways in endothelial cells, inhibited VEGF-A expression in a wound-healing assay, and exhibited interference in the angiogenic process. The gene discussed is VEGFA; the disease is cancer.